PharmaShots | Incisive News in 3 Shots

Subscribe Now

ardelyx

Ardelyx Reports China’s NMPA Approval of Tenapanor for Hyperphosphatemia in Patients

Ardelyx Reports China’s NMPA Approval of Tenapanor for Hyperphosphatemia in Patients

February 27, 2025

Ardelyx Reports the NMPA Acceptance of NDA for Tenapanor to Treat Hyperphosphatemia in China

Ardelyx Reports the NMPA Acceptance of NDA for Tenapanor to Treat Hyperphosphatemia in China

July 14, 2023

Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan

Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan

April 12, 2022

Insights+: The US FDA New Drug Approvals in September and October 2019

Insights+: The US FDA New Drug Approvals in September and October 2019

November 15, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us